BRIGHT MINDS BIOSCIENCES INC (DRUG)
Health Care · Biopharmaceuticals / Clinical-stage drug development · NASDAQ
Clinical-stage biopharmaceutical company developing novel drug therapies, likely focused on psychiatric or neurological indications.
What BRIGHT MINDS BIOSCIENCES INC does
Bright Minds Biosciences is a biopharmaceutical company operating in the healthcare sector. Without access to SEC filing text, the company's precise therapeutic focus and pipeline cannot be confirmed from the available fundamentals alone.
Themes: ["drug development","biotech"]
Fundamentals
- Price$78.20 as of 2026-07-09 close
- Market cap$970M as of 2026-07-10
- 1-year return-74.8% as of 2026-07-09 close
- ROE-20.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.33 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk — as a drug development company, success depends on advancing candidates through trials with uncertain outcomes","Capital intensity — biopharmaceutical development requires significant ongoing funding; with a ~$970M market cap and negative price return, funding availability and burn rate are material risks","Market-specific risk — the -74.8% one-year stock decline suggests significant investor concern about pipeline progress, clinical trial results, or competitive position"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.